A mutational process signature and genomic alterations associated with outcome and immunogenicity in cancers with brain metastasis
By integrating the somatic mutation data of patients with BM, this study identified molecular biomarkers related to outcomes and immunogenicity from three perspectives: mutational process signatures, molecular subtypes, and genomic variations. Our findings provide clues for prognosis evaluation in BM patients. They also establish a theoretical basis for predicting immunotherapy efficacy.
Authors
- Yingzhi Chong (ORCID: https://orcid.org/0000-0002-1335-839X)
- Wenjing Zhang (ORCID: https://orcid.org/0000-0001-6931-900X)
- Xueying Wang (ORCID: https://orcid.org/0000-0001-6445-8887)
- Qinghua Wang (ORCID: https://orcid.org/0000-0002-4289-5813)
- Yixin Xu (ORCID: https://orcid.org/0000-0003-2164-1483)
- Wanli Sun
- Yanfeng Ren
Institutions
- Weifang Medical University (CN)
- Second Hospital of Shandong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-30
- DOI
- https://doi.org/10.3389/fimmu.2025.1607772
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shandong Province
- Tianjin Medical University